A recent study has shown promising results for a new blood test designed to detect colon cancer, a leading cause of cancer-related deaths. The test, which looks for DNA fragments released by tumor cells and precancerous growths, demonstrated an 83% accuracy rate in identifying cancers. However, it was less effective in detecting precancerous growths compared to the gold standard screening method, colonoscopy.
Despite its potential, the blood test has not yet received approval from the Food and Drug Administration and is not covered by most insurance providers. The test is currently available for purchase in the U.S. for $895, with the manufacturer, Guardant Health, expecting an FDA decision later this year.
Colonoscopies remain a crucial tool in preventing colon cancer by removing precancerous polyps. However, many individuals are deterred by the inconvenience of the procedure, including time off work and the preparation involved.
As an alternative, annual stool tests offer a more convenient screening option. These tests involve sending a stool sample to a lab for analysis, providing a less invasive method of screening for colon cancer.
Experts emphasize the importance of increasing screening rates to reduce cancer-related deaths. While colonoscopies are recommended every 10 years for average-risk adults aged 45 to 75, the blood test from Guardant suggests testing every three years, with a follow-up colonoscopy required for abnormal results.
Another study published in the New England Journal of Medicine highlighted an updated version of the Cologuard stool test, which also detects DNA fragments. This improved test showed potential for reducing false alarms and the need for follow-up colonoscopies.
With colorectal cancer ranking high among cancer-related deaths, the availability of multiple screening options is crucial. While some healthcare professionals continue to recommend colonoscopies, the emergence of effective blood tests provides patients with additional choices for early detection and prevention.
Overall, the advancements in colon cancer screening methods offer hope for increasing screening rates and ultimately reducing the burden of this deadly disease.
